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Pemphigus vulgaris (PV) is an autoimmune bullous disease of the skin and
mucous membranes characterized by the presence of circulating and tissue-bound
autoantibodies against keratinocyte cell surface antigens, specifically desmoglein (Dsg)
1 and 3. The pathogenic role of anti-Dsg antibodies is well-established, while the
mechanism of blister formation is only partly defined. We have applied a previously
developed method for the efficient immortalization of IgG+ memory B cells to identify
novel target antigens in PV. A human monoclonal antibody reactive with a hitherto
unreported non-Dsg antigen was isolated. Immunoprecipitation and immunoblotting
studies with keratinocyte extracts indicated α-catenin as the putative antigen, then
confirmed by immunoblotting on the recombinant protein. Four of ten PV sera reacted
with recombinant α-catenin. Although the isolated human monoclonal antibody was per
se unable to dissociate keratinocyte monolayers and also to synergize with a pathogenic
antibody in vitro, further studies are warranted to assess its possible in vivo contribution
in the multifactorial pathogenesis and heterogeneous manifestations of PV disease.
Keywords: pemphigus vulgaris, non-desmoglein autoantigens, autoantibodies, memory B cells, α-catenin, skin,
mucous membranes
INTRODUCTION
Pemphigus vulgaris (PV) is a rare but highly disabling and, if untreated, almost always fatal
immunobullous disease of the skin and mucous membranes. PV is characterized histologically
by loss of cell-cell adhesion between suprabasal keratinocytes, leading to acantholysis, and
immunopathologically by the presence of circulating and tissue-bound autoantibodies (autoAbs)
against keratinocyte cell surface antigens, specifically desmoglein (Dsg) 1 and 3. PV is considered
as a paradigmatic organ-specific autoimmune disease in view of (i) present knowledge of
disease autoantigens and pathogenesis and (ii) reproducibility of major clinical and pathogenic
features in animal models (1). The existence of both pathogenic and non-pathogenic anti-
Dsg autoAbs has recently been underscored by isolation of human monoclonal antibodies
(hMabs) from pemphigus patients. Anti-Dsg hMabs characterization has shown that their
pathogenic potential primarily depends on the targeted epitopes (1). We have been interested in
characterizing the repertoire of naturally occurring autoreactive epithelium-specific memory B
cells in pemphigus vulgaris patients. In a first work, we focused on autoantibodies targeting Dsg3
(2). However, (i) the lack of tight correlation between anti-Dsg autoAb titers and disease activity
in some patients and (ii) the significant degree of disease heterogeneity point at the importance
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of non-Dsg autoAbs, that have been progressively, even though
not exhaustively, described (3, 4). In fact, besides Dsg3 and
Dsg1, other non-desmoglein autoAbs, either pathogenic or non-
pathogenic, have been identified in pemphigus patients. AutoAbs
endowed with an acantholytic potential target desmocollin
3, α-acetylcholine receptor, pemphaxin, and keratinocyte
mitochondria (5–8). On the other hand, the pathogenic role
of autoAbs recognizing other autoantigens, such as ATP2C1,
desmocollin 1, BP230, periplakin, E-cadherin, desmoglein 4,
desmoplakin 1, and desmoplakin 2, remains to be demonstrated
(9). In line with this interest, our current work aimed to
identify autoAbs targeting non-Dsg membrane-bound or
membrane-associated intracellular antigens.
In the present study, we report on the characterization of a
hMab isolated from a PV patient and directed to a novel non-
Dsg antigen. The hMab reacts with α-catenin that is recognized
by almost half of PV sera analyzed.
MATERIALS AND METHODS
Patients, Sera and Isolation of hMabs From
a PV Patient
Peripheral blood was obtained from 2 patients (PVC and PVF)
suffering from active mucocutaneous PV. The patients showed
typical clinical, histological, and immunopathological features
and had high-titer anti-Dsg circulating autoantibodies (PVC:
Dsg3, 127 U/ml, Dsg1, 90 U/ml; PVF: Dsg3, 191 U/ml, Dsg1,
170 U/ml), as assessed by ELISA kits based on ectodomain of
Dsg1 and Dsg3 (MBL, Nagoya, Japan). hMabs were isolated
by a highly-efficient protocol for the immortalization of IgG+
memory B cell with Epstein Barr virus (EBV) in the presence
of a Toll-like receptor agonist, as previously described (2). In
detail, IgG+ memory B cells were isolated from cryopreserved
peripheral blood mononuclear cells using anti-CD22 microbeads
(Miltenyi Biotec, Bo, Italy) followed by depletion of cells
carrying IgM, IgD, and IgA by cell sorting. Multiple replicate
microcultures of 10–30 IgG+ memory B cells/well (for a total of
2 to 8 × 104 purified cells) were infected with EBV and CpG as
previously described (10). Culture supernatants were tested for
binding to Dsg1- and Dsg3-coated ELISA plates and for binding
to HaCaT keratinocyte cell line monolayers (both on live cells
and on fixed and permeabilized cells) by immunofluorescence
(IF) assay using an automated fluorescence microscope (Pathway
855, BD). The specificity of positive polyclonal cultures was
further assessed by IF on primary human keratinocytes. Positive
reactivities were confirmed by the propagation of oligoclonal
cultures. Positive cultures were cloned by limiting dilution and
expanded; antibodies were purified using protein G columns.
Serum samples were collected from 10 PV and 16 bullous
pemphigoid (BP) patients and 10 healthy donors. This study was
carried out in conformity with the Helsinki guidelines and with
approval of the IDI-IRCCS Ethics Committee. All the biological
samples were obtained after patient’s informed consent.
Immunofluorescence Analyses
IF studies were performed according to the procedure described
in Di Zenzo et al. with minor modifications (2). Briefly,
supernatants from immortalized human memory B cells were
screened on monolayers of live and fixed/permeabilized HaCaT
cells. After washing with phosphate-buffered saline, cells were
stained with Alexa Fluor 488–conjugated goat anti-human IgG
(Invitrogen, Carlsbad, CA, USA). The isolated monoclonal
antibodies were further tested on permeabilized HaCaT cells
and on primary keratinocytes. Non-keratinocyte cell lines, i.e.,
MRC9, Hela, and SKMEL cells, were used as controls for IF
analyses on cell monolayers. Human antibodies of irrelevant
specificity were used as negative controls. Serial images of stained
keratinocyte monolayers were acquired by the BD Pathway 855
automated fluorescencemicroscope. Staining was also performed
on cryo sections of normal human skin, guinea pig and
monkey esophagus and revealed with fluorescein isothiocyanate-




Immunoprecipitation (IP) of 35S-labeled keratinocyte extracts
by hMab PVF144 was carried out as previously described (11).
The precipitated proteins, separated on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis on 6% gels under reducing
conditions, were detected by autoradiography. Immunoblotting
(IB) experiments on keratinocyte extracts were performed as
previously reported using both horseradish peroxidase (HRP)-
conjugated and alkaline phosphatase-conjugated secondary
antibodies (12). Bands were quantified using ImageJ Software
(National Institutes of Health, Bethesda, MD, USA) and
their intensities were normalized respect to the positive
control signal obtained by anti-α-catenin antibody. The cut-
off value was set as the medium value +2 standard deviations
obtained measuring signals obtained with healthy donors.
Commercial primary antibodies were purchased from Progen
Biotechnik GmbH (Heidelberg, Germany) (anti-desmocollin 2),
BD Biosciences (San Jose, CA, USA; anti-α-catenin), and Santa
Cruz Biotechnology, Inc (Dallas, TX, USA; anti-γ-catenin, anti-
β-catenin, anti-p120, and anti-E-cadherin). Recombinant tagged
human α1-catenin was purchased from Abcam (Cambridge,
UK). To rule out that PV sera were mainly reacting against the
fused glutathione S-transferase (GST) moiety of the α-catenin
recombinant protein, IB experiments by using commercial




Briefly, recombinant Dsg1 and Dsg3 ectodomains were produced
in baculovirus and used for coating of ELISA plates. The
plates were, then, blocked with 1% bovine serum albumin and
incubated with antibodies followed by HRP-conjugated anti-
human IgG (Jackson ImmunoResearch, Baltimore, PA, USA) (2).
Keratinocyte Dissociation Assay
The assay was performed as previously reported (13). Briefly,
primary human keratinocyte cells were seeded onto 12-well plates
and 24 h post-confluence treated with monoclonal antibodies.
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After adding exfoliative toxin A to cleave Dsg1 protein, the
cell monolayers were detached with dispase I (Merck, KGaA,
Darmstadt, Germany) and subjected to mechanical stress by
pipetting. The monolayer fragments, fixed by adding a 3%
formaldehyde solution, were subsequently stained using crystal
violet. To investigate a possible synergistic effect PVF144 was
applied to the monolayer together with a pathogenic antibody
(PVB28) (2) at optimal (4µg/ml) and suboptimal concentrations
(1µg/ml and 0.25µg/ml; Figure 4) and a non-pathogenic
antibody (2, PVB28 in a germline version that is not able to
dissociate the keratinocyte monolayer; data not shown).
RESULTS
Isolation of hMabs Specific for Non-Dsg
Epithelial Antigens in Pemphigus Patients
In order to identify hMabs targeting non-Dsg membrane-
bound or membrane-associated intracellular antigens, we
took advantage of the same strategy by which we had
previously isolated and finely characterized several Dsg-reactive
PV patient-derived monoclonal autoantibodies (2). In detail,
peripheral blood samples were collected from 2 patients with
mucocutaneous PV: one with long-lasting steroid-resistant
disease (PVC) and the other prior to treatment initiation
(PVF). IgG+ memory B cells were isolated by magnetic and
fluorescence-activated cell sorting, seeded in 96-well microplates,
and immortalized with EBV in the presence of irradiated
mononuclear cells and oligodeoxynucleotides containing CpG
motifs, as previously described (10). The reactivity of antibodies
secreted in the supernatants of growing polyclonal cultures
was screened by IF staining both on live and on fixed
and permeabilized cells from the human keratinocyte HaCaT
cell line. The polyclonal antibodies produced by the vast
majority of isolated cultures bound to surface antigens on the
keratinocyte membrane and were reactive with Dsg1 and/or
Dsg3 ectodomains by ELISA, as previously reported (2, and
data not shown). Besides such prevalent pattern of reactivity,
supernatants of rare cultures from both patients showed a
distinctive membrane-associated fishnet reactivity, detected only
on permeabilized keratinocytes, and were negative in ELISA
on Dsg1 and Dsg3 ectodomains. The human Mabs PVF144
(IgG1-isotype), PVC6 (IgG1-isotype), and PVC33 (isotype IgG3-
isotype) were cloned by limiting dilution and showed the same IF
pattern as the original polyclonal cultures also on permeabilized
HaCaT keratinocytes (Figure 1A), suggesting their specificity
for a membrane-associated intracellular (i.e., non-exposed)
autoantigen. In addition, they showed an intercellular staining
pattern by IF on human skin, guinea pig, and monkey esophagus
(Figures 1B–D), very similar to IF staining pattern of anti-
Dsg3 antibodies (2, and data not shown). Supernatants from the
selected clones were tested on non-keratinocyte cell lines, i.e.,
MRC-9 (fibroblast), SKMEL (melanoma), and Hela (epithelial)
cells: they failed to stain both live and permeabilized cells, apart
from a reactivity on permeabilized Hela cells (data not shown),
hinting at a specificity for membrane-associated intracellular
antigens expressed on keratinocytes and other epithelial cells.
FIGURE 1 | Intercellular staining pattern of hMab PVF144. PVF144 binds a
membrane associated epithelial antigen showing a typical intercellular staining
pattern on permeabilized HaCaT keratinocytes (nuclear counterstain is
obtained with DAPI) (20X) (A), human skin (40X) (B) guinea pig (40X) (C), and
monkey esophagus (40X) (D).
Identification of the Intracellular Epithelial
Target Antigen of hMab PVF144
IP studies with the 3 selected clones on radiolabelled keratinocyte
extracts to identify the target antigen showed reactivity to a
100 kDa antigen for PVF144 (Figure 2A) and to 190–210 kDa
antigens for PVC6 and PVC33, respectively (data not shown). As
the IP results from the latter two clones pointed at members of
the plakin-family as candidate target antigens and autoreactivity
of PV sera to plakin family members has been already
documented (14, 15), we chose to further characterize PVF144
with the aim to identify a possible novel membrane-associated
PV autoantigen. Subsequent IB experiments using commercial
antibodies reacting with keratinocyte membrane-associated
proteins with a molecular weight of ∼100 kDa (desmocollin 2–
115 kDa; α-catenin-102 kDa; E-cadherin-120 kDa; β-catenin-
92 kDa; γ-catenin-83 kDa; P120-catenin 80–100 kDa) indicated
α-catenin as the putative antigen (Figure 2B). Sequential IP
and IB experiments further supported α-catenin as the target
antigen of PVF144. Specifically, a protein immunoprecipitated
from keratinocyte extracts with PVF144 was recognized by
a commercial anti-α-catenin antibody, and an anti-α-catenin
antibody was in turn able to immunoprecipitate a protein
recognized by PVF144 in IB (Figure 2C). Finally, IB experiments
with the recombinant tagged protein unequivocally confirmed
the specific binding of PVF144 to α-catenin (Figure 2D).
α-Catenin Is Recognized by PV Patient
Sera
To determine whether autoAbs of the same specificity as PVF144
were present in the sera of PV patients, we performed IB
experiments with 10 PV sera on recombinant tagged α-catenin
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FIGURE 2 | PVF144 binds a membrane-associated epithelial antigen: α-catenin. PVF144 immunoprecipitates (IP) an unknown antigen of 100 kDa from radiolabeled
normal human keratinocyte extracts (A). Immunoblotting (IB) experiments on keratinocyte extracts by using PVF144 and commercial antibodies suggest that
α-catenin could be the putative antigen of 100 kDa: PVF144 and a monoclonal murine anti-α-catenin antibody (Ab) react with a keratinocyte antigen of similar
molecular weight (100 kDa) (B). Anti-α-catenin commercial antibody reacts to α-catenin from keratinocyte extracts by IB (lane 1); PVF144 immunoprecipitates
α-catenin recognized by the commercial anti-α-catenin antibody by IB (lane 2) and, viceversa, anti-α-catenin antibody immunoprecipitates α-catenin recognized by
PVF144 by IB (lane 3). The faint reactivity observed in lane 3 could be related to the epitope recognized (C). IB performed with a recombinant GST-tagged human
α-catenin (120 kDa) confirms that the target of PVF144 is α-catenin. The lower bands are likely degradation products (D).
(Figure 3). Four out of 10 PV patients (40%) showed the same
reactivity of PVF144 to α-catenin, whereas the other PV sera
and 10 normal human control sera showed only a faint signal,
indicating that this autoreactivity was well-represented in PV
patients, even though not shared by all patients. In order to
evaluate whether this reactivity is disease-specific, 16 BP patient
sera were analyzed on recombinant α-catenin by IB. Only one of
16 BP (7 representative BP sera shown and other 9 not shown)
reacted to α-catenin (Supplementary Figure 1) underlining the
specificity of this autoantigen. The weak signals found in the
other remaining PV, PB, and healthy donor sera might be
ascribed to reactivity to the tag protein (GST).
PVF144 Is Not Able to Dissociate a
Keratinocyte Monolayer and to Synergize
With a Human Pathogenic Antibody
The presence of anti-α-catenin autoAbs in several PV sera raised
the question as to their pathogenic potential. Previous studies
showed the ability of intact autoAbs to enter the cytosol or
nucleus of living cells (16, 17). More recently, Marchenko et al.
reported that PV autoAbs could penetrate keratinocytes and react
with intracellular mitochondrial proteins (8). These findings
suggested that a hMab to an intracellular antigen could exert
its pathogenic ability on live keratinocytes. Thus, an in vitro
dissociation assay was used to evaluate the pathogenic activity of
the hMab PVF144. This approach allows to measure the ability of
a specific antibody or a mixture of antibodies, such as a serum,
to fragment a monolayer of primary human keratinocytes seeded
to confluence. The keratinocyte monolayers, incubated for 24 h
with PVF144, remained intact, similarly to monolayers incubated
with an unrelated hMab used as negative control (Figure 4).
As expected, human (PVB28) and murine (AK23) pathogenic
anti-Dsg3 antibodies were able to dissociate the monolayers
(2, 18) (Figure 4). In addition, PVF144 failed to synergize with
a pathogenic antibody (Figure 4). These findings exclude a
primary pathogenic function of anti-α-catenin autoAbs in PV,
nevertheless a potential secondary role in the immunobiology of
the disease cannot be excluded and warrants future studies.
DISCUSSION
In the present work we went forward in the characterization
of the diverse targets of epithelium-specific autoreactive B cells
from PV patients. To this purpose, we took advantage of the
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FIGURE 3 | Almost half of PV sera specifically react with recombinant α-catenin. Immunoblotting with sera obtained from 10 pemphigus vulgaris (PV) patients shows
that 4 of 10 sera (4, 8, 9, 10) react with the novel epithelial antigen, while 3 healthy donor sera (11, 12, 13), representative of 10 sera analyzed, show only a
background signal. The positive control (C+) is the commercial anti-α-catenin antibody. The background signal, could be also due to reactivity to the tag protein
(GST). Quantification and normalization of bands using ImageJ analysis (data not shown) have confirmed the reported results (see Materials and Methods section).
high-efficiency immortalization protocol of IgG+ memory B
cells we had previously developed (10) and applied to isolate
and molecularly characterize a number of anti-Dsg3 hMabs (2).
Our present focus was to detect plasma-membrane-associated
antigens, either expressed on the cell surface or intracellularly,
therefore we chose to screen the isolated polyclonal cultures on
both live and permeabilized keratinocytes. Our choice was based
on the hypothesis that antigens associated to the cell membrane,
even those with intracellular localization, could have a higher
chance to contribute to pemphigus pathogenesis, which is due to
the loss of cell-cell adhesion.
As expected, the vast majority of cultures resulted specific
for Dsg1 and/or Dsg3, further confirming the major role of
these antigens in pemphigus pathogenesis. Among polyclonal
cultures that reacted only with permeabilized keratinocytes,
we selected and cloned those giving a membrane-associated
fishnet-like staining pattern on stratified epithelia. Among the
cloned cultures, we further characterized clone PVF144 and
demonstrated by IF, IP and IB studies that α-catenin is its target.
α-catenin is a component of adherens junctions (AJs), i.e., cell-
cell anchoring structures that, together with desmosomes, allow
keratinocytes to adhere to one another and maintain epithelial
integrity. α-catenin binds to β-catenin in AJs and is required for
their formation and maintenance (19, 20). In addition, α-catenin
was reported to be necessary for the organization of desmosomes
in epithelial cells (21).
A previous study reported a reactivity of pemphigus sera
to another AJ component, i.e., E-cadherin (22). Likewise,
we showed that anti-α-catenin autoreactivity was: (i) well-
represented in PV patient sera, as α-catenin was recognized by
almost half of the PV sera tested; (ii) more frequently associated
with pemphigus than with other autoimmune bullous diseases, as
α-catenin was very rarely recognized by the BP sera analyzed.
Then, considering that previous studies demonstrated the
ability of intact autoAbs to enter living cells (8, 16, 17),
we addressed the potential pathogenicity of α-catenin-specific
Mab PVF144 by evaluating its acantholytic activity in an in
vitro keratinocyte dissociation assay. In this regard, several
observations suggest that AJs, and in particular E-cadherin,
may be involved in pemphigus pathogenesis (23, 24). Of
note, with the exception of anti-desmocollin 3 autoAbs, all
known non-Dsg-reactive autoAbs with reported pathogenicity
do not possess acantholytic potential on their own but may act
synergistically with anti-Dsg antibodies (1, 25, 26). Accordingly,
Marchenko et al. described a pathogenic role for intracellular
anti-mitochondrial autoAbs, even though not on their own
(8). In our hands, the anti-α-catenin Mab PVF144 was not
able to dissociate the keratinocyte monolayer either alone or
in combination with a suboptimal dose of a pathogenic anti-
Dsg3 antibody. Nevertheless, we cannot exclude that regions
of α-catenin different from that recognized by PVF144 could
be recognized by PV sera and contribute to acantholysis.
In addition, a possible role of anti-α-catenin hMabs as co-
factors in disease initiation or maintenance could not be
exhaustively addressed by our approach. In previous studies,
several antibodies against intracellular antigens have been
considered as triggers for autoimmunity. Mabs specific for
the cytoplasmic precursor form of Dsg1 (preDsg1) have been
cloned from pemphigus patients and from healthy individuals
(25, 26). Yamagami et al. postulated that the presence of
anti-preDsg1 B cells is involved in the initiation of the
autoimmune response in pemphigus patients. In particular, in
the context of tissue damage they could present peptides which
are part of mature Dsg1 (i.e., the extracellular autoantigen
recognized by most pathogenetic autoAbs) derived from the
processing of preDsg1. This intramolecular epitope spreading
phenomenon could lead to the production of pathogenic
autoAbs targeting mature Dsg1 and to the initiation of disease
pathogenesis (27, 28). Moreover, natural autoAbs (NAAs), i.e.,
antibodies to intracellular autoantigens that naturally occur in
the healthy population and are per se unable to cause immune
phatology, have been theorized as cofactors in the onset of
autoimmunity, possibly by participating in the mechanisms of
chronic tissue injury at the basis of intermolecular epitope
spreading (29–31).
In conclusion, while our previous study (2) demonstrated
that pathogenic PV antibodies primarily target the Dsg-3 cis-
interface, thus leading to desmosome disruption, our current
results reveal novel antibodies targeting intracellular keratinocyte
proteins. We are tempted to speculate that the cellular damage
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FIGURE 4 | PVF144 is not able to dissociate a keratinocyte monolayer even in the presence of suboptimal concentrations of PVB28. A representative keratinocyte
dissociation experiment. Primary human keratinocytes, seeded to confluence, were incubated with PVF144, an unrelated human Mab (negative control) and, as
positive controls, the human pathogenic Mab PVB28 (7) and the murine pathogenic Mab AK23 (14), both Dsg3-specific (A). To investigate synergistic potential of
cloned antibody we have employed PVF144 (10µg/ml) together with optimal (4µg/ml) and suboptimal concentrations (1µg/ml and 0.25µg/ml) of the pathogenic
anti-Dsg3 antibody PVB28 without obtaining any difference in ability of PVB28, with or without PVF144, to dissociate the keratinocyte monolayer (B).
induced by pathogenic anti-Dsg antibodies may trigger an
intermolecular epitope-spreading phenomenon resulting in an
antibody response against intracellular antigens, among which
α-catenin. Further studies are needed: (i) to evaluate whether
PVF144 may act synergistically with anti-Dsg antibodies using
more informative approaches, such as in vitro organ culture or
in vivo models; (ii) to assess the possible role of anti-α-catenin
autoAbs in pemphigus initiation and evolution in vivo; and (iii)
to characterize this novel antigen as a possible target of epitope
spreading phenomena in PV.
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